GGrantIndex
← Leaderboards

Jean Zhao

Dana-Farber Cancer Inst

Google Scholar ↗PubMed ↗ORCID ↗
$18,430,855
Attributed
$20,699,229
Total exposure
11
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY2008–25
$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,699,229 · 11

By mechanism

R35$9,800,368 · 1
R01$6,050,552 · 3
P50$3,047,826 · 4
P01$994,202 · 1
R21$406,281 · 1
R41$400,000 · 1

Top collaborators

Most similar at Dana-Farber Cancer Inst

Same institution · by research overlap

Others in their field

Top investigators on “Pten Gene”

Research focus

Pten GeneMalignant Breast NeoplasmTumorGeneticTargeted TreatmentSignal TransductionPathway InteractionsPre-ClinicalMouse ModelResponseMalignant NeoplasmsEffective TherapyAffectSamplingMolecularTreatment StrategyProtein IsoformsBrainImmunotherapyCellsCancer TherapyPharmaceutical PreparationsOncogenicResistance

Grant awards (39)

Integrating targeted therapy and immunotherapy to break through cancer$1,027,633
R35 · FY2025 · CA · contact PI
Targeting replication stress to engage DNA sensing STING pathway derived anti-tumor immunity to improve the therapeutic outcomes in uterine cancer$482,771
P01 · FY2025 · CA · contact PI
Integrating targeted therapy and immunotherapy to break through cancer$976,251
R35 · FY2024 · CA · contact PI
Targeting replication stress to engage DNA sensing STING pathway derived anti-tumor immunity to improve the therapeutic outcomes in uterine cancer$511,431
P01 · FY2024 · CA · contact PI
Integrating targeted therapy and immunotherapy to break through cancer$1,027,633
R35 · FY2023 · CA · contact PI
Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration$400,000
R41 · FY2023 · CA · contact PI
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)$303,523
P50 · FY2023 · CA · contact PI
Project 3: Improving therapeutic approaches for breast cancer brain metastases$277,115
P50 · FY2023 · CA · contact PI
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer$987,088
R35 · FY2022 · CA · contact PI
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)$303,523
P50 · FY2022 · CA · contact PI
Project 3: Improving therapeutic approaches for breast cancer brain metastases$263,646
P50 · FY2022 · CA · contact PI
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer$1,007,233
R35 · FY2021 · CA · contact PI
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)$353,666
P50 · FY2021 · CA · contact PI
Project 3: Improving therapeutic approaches for breast cancer brain metastases$305,118
P50 · FY2021 · CA · contact PI
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer$1,007,233
R35 · FY2020 · CA · contact PI
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)$358,834
P50 · FY2020 · CA · contact PI
Project 3: Improving therapeutic approaches for breast cancer brain metastases$295,119
P50 · FY2020 · CA · contact PI
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)$264,010
P50 · FY2020 · CA · contact PI
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer$977,015
R35 · FY2019 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$537,433
R01 · FY2019 · CA
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)$323,272
P50 · FY2019 · CA · contact PI
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer$1,007,233
R35 · FY2018 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2018 · CA
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer$1,007,233
R35 · FY2017 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2017 · CA
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer$775,816
R35 · FY2016 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2016 · CA
Targeting the p110beta Isoform of PI3 Kinase in Pten Null Tumors$413,558
R01 · FY2016 · CA · contact PI
Targeting the p110beta isoform of PI3 kinase in prostate cancer$554,053
R01 · FY2015 · CA
Targeting the p110beta Isoform of PI3 Kinase in Pten Null Tumors$413,558
R01 · FY2015 · CA · contact PI
(PQD4) Epigenetic loss of heterozygosity as a driver of the cancer field effect$184,327
R21 · FY2015 · CA
Targeting the p110beta Isoform of PI3 Kinase in Pten Null Tumors$401,152
R01 · FY2014 · CA · contact PI
(PQD4) Epigenetic loss of heterozygosity as a driver of the cancer field effect$221,954
R21 · FY2014 · CA
Targeting the p110beta Isoform of PI3 Kinase in Pten Null Tumors$413,558
R01 · FY2013 · CA · contact PI
Roles of class 1A PI3K isoforms in mammary epithelium function and breast cancer$324,985
R01 · FY2012 · CA · contact PI
Roles of class 1A PI3K isoforms in mammary epithelium function and breast cancer$324,985
R01 · FY2011 · CA · contact PI
Roles of class 1A PI3K isoforms in mammary epithelium function and breast cancer$335,037
R01 · FY2010 · CA · contact PI
Roles of class 1A PI3K isoforms in mammary epithelium function and breast cancer$335,037
R01 · FY2009 · CA · contact PI
Roles of class 1A PI3K isoforms in mammary epithelium function and breast cancer$335,037
R01 · FY2008 · CA · contact PI